WEGOVY 1.75 MG

Wegovy 1.75 mg – Pre-Maintenance Dose of Semaglutide | Novo Nordisk

Wegovy 1.75 mg is a pre-filled subcutaneous pen developed by Novo Nordisk, designed to deliver a weekly dose of Semaglutide as part of a progressive titration protocol. This intermediate-strength pen bridges the transition between 1.0 mg and the final 2.4 mg maintenance dose. It is intended strictly for research use in studies related to obesity, metabolic health, and GLP-1 receptor agonist effects.

Semaglutide and GLP-1 Pathway Activation

Semaglutide is a long-acting GLP-1 analog that promotes satiety, slows gastric emptying, and improves insulin sensitivity. Its mechanism of action targets both peripheral and central pathways that regulate hunger and energy balance. In published clinical trials, Semaglutide induced significant reductions in body weight, waist circumference, and HbA1c levels when administered weekly.

Wegovy 1.75 mg in Research Settings

This 1.75 mg pen is used after titration through 0.25 mg, 0.5 mg, and 1.0 mg doses. It precedes the full 2.4 mg maintenance dose and allows researchers to assess tolerance and optimize therapeutic effects. It is injected once per week subcutaneously, typically in the abdomen, thigh, or upper arm.

Research Applications

• Appetite suppression and behavioral eating intervention studies
• Chronic obesity and metabolic syndrome modeling
• Fat mass reduction in combination with dietary protocols
• Insulin resistance and GLP-1 mediated glycemic control
• Neuroendocrine signaling and energy balance

Suggested Peptide Stack Combinations

Semaglutide research protocols often benefit from stacking with other metabolic and regenerative compounds for broader impact:

• AOD 9604 – enhances fat metabolism without affecting glucose levels
• CJC-1295 no DAC – supports GH release to preserve lean mass
• GHK-Cu – supports glucose balance, tissue recovery, and inflammation control
• BPC-157 – used for GI healing and stress recovery during calorie restriction

Pharmacological Notes & Safety

Semaglutide has a 7-day half-life, enabling consistent plasma levels with weekly injections. GI discomfort such as nausea or early satiety may occur as the dose increases, but most effects subside over time. Semaglutide does not aromatize or disrupt hormone levels and is non-hepatotoxic. Its profile is favorable in both short- and long-term preclinical weight loss research.

USA Domestic Availability

Wegovy 1.75 mg pens are manufactured by Novo Nordisk and handled under cold-chain conditions. Dragon Pharma Store ensures fast, tracked USA domestic shipping with guaranteed quality. Also available are earlier titration phase options like Wegovy 1 mg or the injectable research-grade Dragon Pharma Semaglutide in vial form.

Frequently Asked Questions